Stocks · News reference
Following Type C FDA Meeting, Calcimedica Has Aligned On Phase 2b Trial Endpoints And Patient Population Enrichment Strategy For Its Planned Registration Program Evaluating Auxora In Acute Pancreatitis
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 11:13 AM
- Checked
- Jul 29, 2026, 11:12 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — CalciMedica, Inc. (CALC)
Filed: 2026-08-27 AccNo: 0001193125-26-369713 Size: 163 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Read original at edgarCalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
Read original at benzingaGuggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
Read original at benzinga